

## Refine Search

### Search Results -

Term	Documents
BETA	462596
BETAS	905
INTERFERON	30462
INTERFERONS	11729
IFN	12633
IFNS	863
(11 AND (IFN OR (BETA ADJ INTERFERON) OR INTERFERON)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	47
(L11 AND ((BETA ADJ INTERFERON) OR IFN OR INTERFERON) ).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	47

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

Refine Search

Recall Text

Clear

Interrupt

### Search History

DATE: Friday, May 14, 2004    [Printable Copy](#)    [Create Case](#)

Set Name    Query  
 side by side

Hit Count

Set  
Name  
 result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES;  
 OP=AND

<u>L13</u>	L11 and ((beta adj interferon) or IFN or interferon)	47	<u>L13</u>
<u>L12</u>	L11 and L9	3	<u>L12</u>
<u>L11</u>	(insect adj cell) same (adjuvant)	139	<u>L11</u>

<u>L10</u>	L9 and L7	1	<u>L10</u>
<u>L9</u>	(inactivated or inactive) same (cancer adj cell)	824	<u>L9</u>
<u>L8</u>	L7 same (claim)	0	<u>L8</u>
<u>L7</u>	L6 same (treatment or therapy)	284	<u>L7</u>
<u>L6</u>	(beta adj interferon) same (cancer or tumor)	2038	<u>L6</u>
<u>L5</u>	L2 and ((inactivated or inactive) adj cancer)	0	<u>L5</u>
<u>L4</u>	L2 not L3	26	<u>L4</u>
<u>L3</u>	L2 and (interferon adj beta)	39	<u>L3</u>
<u>L2</u>	(cancer) same (insect and interferon?)	65	<u>L2</u>
<u>L1</u>	Fidler-Isaiah-J\$.in.	10	<u>L1</u>

END OF SEARCH HISTORY



Day : Friday  
Date: 5/14/2004

Time: 16:22:37

## Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.  
Additionally, enter the **first few letters** of the Inventor's First name.

**Last Name**

**First Name**

Fidler

Isaiah

Search

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

### Status: Path 1 of [Dialog Information Services via Modem]

### Status: Initializing TCP/IP using (UseTelnetProto 1 ServiceID pto-dialog)  
Trying 31060000009999...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

\*\*\*\*\* HHHHHHHH SSSSSSSS?

### Status: Signing onto Dialog

\*\*\*\*\*

ENTER PASSWORD:

\*\*\*\*\* HHHHHHHH SSSSSSSS? \*\*\*\*\*

Welcome to DIALOG

### Status: Connected

Dialog level 04.08.00D

Last logoff: 07may04 10:00:07

Logon file001 14may04 15:58:58

\*\*\* ANNOUNCEMENT \*\*\*

\*\*\*

--File 654 - US published applications from March 15, 2001 to the present are now online. Please see HELP NEWS 654 for details.

\*\*\*

--File 581 - The 2003 annual reload of Population Demographics is complete. Please see Help News581 for details.

\*\*\*

--File 990 - NewsRoom now contains February 2003 to current records.  
File 992 - NewsRoom 2003 archive has been newly created and contains records from January 2003. The oldest months's records roll out of File 990 and into File 992 on the first weekend of each month.  
To search all 2003 records BEGIN 990, 992, or B NEWS2003, a new OneSearch category.

\*\*\*

--Connect Time joins DialUnits as pricing options on Dialog.  
See HELP CONNECT for information.

\*\*\*

\*\*\*

--SourceOne patents are now delivered to your email inbox as PDF replacing TIFF delivery. See HELP SOURCE1 for more information.

\*\*\*

--Important Notice to Freelance Authors--  
See HELP FREELANCE for more information

\*\*\*

NEW FILES RELEASED

\*\*\*AeroBase (File 104)

\*\*\*DIOGENES: Adverse Drug Events Database (File 181)

\*\*\*World News Connection (File 985)

\*\*\*Dialog NewsRoom - 2003 Archive (File 992)

\*\*\*TRADEMARKSCAN-Czech Republic (File 680)

\*\*\*TRADEMARKSCAN-Hungary (File 681)

\*\*\*TRADEMARKSCAN-Poland (File 682)

\*\*\*

UPDATING RESUMED

\*\*\*

RELOADED

\*\*\*Medline (Files 154-155)

\*\*\*Population Demographics -(File 581)

\*\*\*CLAIMS Citation (Files 220-222)

REMOVED

\*\*\*

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<  
>>> of new databases, price changes, etc. <<<  
\*\*\*\*\*

KWIC is set to 50.  
HIGHLIGHT set on as '\*'  
\* ALL NEW CURRENT YEAR RANGES HAVE BEEN \* \* \*  
\* \* \* INSTALLED \* \* \*  
\*

File 1:ERIC 1966-2004/Apr 29  
(c) format only 2004 The Dialog Corporation

Set	Items	Description
-----	-------	-------------

Cost is in DialUnits

?b 155, 159

14may04 15:59:14 User259876 Session D621.1

\$0.33 0.095 DialUnits File1

\$0.33 Estimated cost File1

\$0.06 TELNET

\$0.39 Estimated cost this search

\$0.39 Estimated total session cost 0.095 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1966-2004/May W2

(c) format only 2004 The Dialog Corp.

**\*File 155: Medline has been reloaded. Accession numbers**  
have changed. Please see HELP NEWS 154 for details.

File 159:Cancerlit 1975-2002/Oct

(c) format only 2002 Dialog Corporation

**\*File 159: Cancerlit ceases updating with immediate effect.**  
Please see HELP NEWS.

Set	Items	Description
-----	-------	-------------

?s (systemic (w) interferon (w) beta (w) administration)

219519 SYSTEMIC

145239 INTERFERON

579707 BETA

1374757 ADMINISTRATION

S1 0 (SYSTEMIC (W) INTERFERON (W) BETA (W) ADMINISTRATION)

?s (systemic (w) beta (w) interferon (w) administration)

219519 SYSTEMIC

579707 BETA

145239 INTERFERON

1374757 ADMINISTRATION

S2 0 (SYSTEMIC (W) BETA (W) INTERFERON (W) ADMINISTRATION)

?s (beta (w) interferon) or (IFN (w) beta) or (interferon (w) beta)

579707 BETA

145239 INTERFERON

3289 BETA(W) INTERFERON

77912 IFN

579707 BETA

4749 IFN(W) BETA

145239 INTERFERON

579707 BETA

7223 INTERFERON(W) BETA

S3 11055 (BETA (W) INTERFERON) OR (IFN (W) BETA) OR (INTERFERON  
(W) BETA)

?s s3 (s) (treatment or therapy)

11055 S3

1943902 TREATMENT

2468644 THERAPY

S4 4014 S3 (S) (TREATMENT OR THERAPY)

?s s4 (s) (cancer or tumor)

4014 S4  
 826371 CANCER  
 1064068 TUMOR  
 S5 942 S4 (S) (CANCER OR TUMOR)  
 ?s s5 and (systemic (w) administration)  
 942 S5  
 219519 SYSTEMIC  
 1374757 ADMINISTRATION  
 7715 SYSTEMIC(W)ADMINISTRATION  
 S6 8 S5 AND (SYSTEMIC (W) ADMINISTRATION)  
 ?rd  
 ...completed examining records  
 S7 5 RD (unique items)  
 ?t s7/3,k/all

**7/3,K/1 (Item 1 from file: 155)**  
 DIALOG(R)File 155:MEDLINE(R)  
 (c) format only 2004 The Dialog Corp. All rts. reserv.

15952003 PMID: 12944985

**Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-beta gene and poly I: poly C in a murine lung metastasis model.**

Sakurai Fuminori; Terada Takeshi; Maruyama Masato; Watanabe Yoshihiko; Yamashita Fumiyoshi; Takakura Yoshinobu; Hashida Mitsuru

Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.

Cancer gene therapy (England) Sep 2003, 10 (9) p661-8, ISSN 0929-1903 Journal Code: 9432230

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

We have evaluated and compared the efficacy of \*systemic\* administration\* of lipoplex formulations containing plasmids encoding IFN-beta or IFN-gamma, and a synthetic double-strand RNA poly I:poly C (pI:pC), a type...

... mice. Injection of lipoplexes containing plasmid DNA, regardless of IFN gene insertion, stimulated a transient increase in the serum concentration of proinflammatory cytokines such as \*tumor\* necrosis factor (TNF)-alpha and IFN-gamma, while injection of lipoplexes containing pI:pC led to a low level of TNF-alpha and undetectable IFN...

... in the production of a mixture of type I and type II IFNs, partly derived from the inserted IFN genes, in lung tissue cultures. In \*tumor\* -prophylactic experiments, intravenous injection of lipoplexes containing plasmid, regardless of IFN gene insertion, showed a significant reduction in lung metastatic nodules probably due to proinflammatory...

... experiments, a single intravenous administration of lipoplexes containing IFN-beta gene or pI:pC, but not other lipoplexes, showed a significant therapeutic effect on the \*tumor\* metastasis: reduction in \*tumor\* nodules and prolongation of survival time of \*tumor\*-burden mice. The therapeutic effects were specifically impaired by anti-IFN-beta antibody \*treatment\*, indicating that \*IFN\*-beta\* produced by the lipoplexes played an important role in the suppression of established metastatic lung tumors. Thus, the local \*IFN\*-beta\* in the lung delivered by intravenous administration of lipoplex containing \*IFN\*-beta\* gene or pI:pC may be a convenient and useful method of inhibiting established metastatic lung tumors.

**7/3,K/2 (Item 2 from file: 155)**  
 DIALOG(R)File 155:MEDLINE(R)  
 (c) format only 2004 The Dialog Corp. All rts. reserv.

10724793 PMID: 10845718

**Anti-inflammatory action of type I interferons deduced from mice expressing interferon beta.**

Bosca L; Bodelon O G; Hortelano S; Casellas A; Bosch F

Instituto de Bioquímica (Centro Mixto CSIC-UCM), Facultad de Farmacia, Universidad Complutense, Madrid, Spain.

Gene therapy (ENGLAND) May 2000, 7 (10) p817-25, ISSN 0969-7128

Journal Code: 9421525

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... immune system, in particular in the activation of macrophages. To study the systemic effects of type I IFNs we used transgenic mice carrying a human \*IFN\*-beta\* (hIFN-beta) gene under the control of the rat insulin I promoter. These animals expressed high levels of hIFN-beta in beta-pancreatic cells, and...

...the serum levels of TNF-alpha and an inhibition of the activation of the transcription factor NF-KB in various tissues. These results indicate that \*systemic\* \*administration\* of \*IFN\*-beta\* might influence the response to pro-inflammatory stimuli, in particular through the antagonism of IFN-gamma signaling.

7/3,K/3 (Item 3 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

09088450 PMID: 1658686

**The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma--a phase II study.**

von Wild K R; Knocke T H

Neurosurgical Department, Clemenshospital Munster, Fed. Rep. of Germany.

Neurosurgical review (GERMANY) 1991, 14 (3) p203-13, ISSN 0344-5607

Journal Code: 7908181

Document type: Clinical Trial; Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... to the highly promising and, with rates up to 40%, surprisingly high response rates of malignant supratentorial brain gliomas to post-operative adjuvant IFN beta \*therapy\*, we were unable to demonstrate any definite anti-proliferative, anti-\*tumor\* or immunomodulatory effects of interferon in a phase II study in 13 patients. We used high doses of an \*IFN\* \*beta\*, Fiblaferon, whose potency was repeatedly confirmed by pharmacokinetic investigations, for local and \*systemic\* \*administration\*, and the times of administration were those used in the Japanese comparative studies. The side effects observed proved to be related to the amount of \*IFN\* \*beta\* administered and its duration in our patients as well. In this context, the neurotoxic disturbances require particular attention. These resolved completely after discontinuation of IFN \*treatment\*, as do the haematological and liver enzyme disturbances after suspension of medication. We did not observe any improvement in the post-operative quality of life, nor, above all, any improvement in long-term prognosis resulting from a prolonged \*tumor\*-free remission period and prolongation of the actual post-operative survival time.

7/3,K/4 (Item 4 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

07591582 PMID: 3499528

**[Radiotherapy combined with BRM (biological response modifiers) in the**

**treatment of cancer]**

Okawa T; Goto M; Kita M

Dept. of Radiology, Tokyo Women's Medical College.

Gan no rinsho. Japan journal of cancer clinics (JAPAN) Aug 1987, 33

(10) p1253-6, ISSN 0021-4949 Journal Code: 1257753

Erratum in Gan No Rinsho 1987 Oct;33(13) 1687

Document type: Journal Article ; English Abstract

Languages: JAPANESE

Main Citation Owner: NLM

Record type: Completed

... response modifiers (BRM) with or without another cancer treatment modalities has been increased. In this paper, radiotherapy combined with some BRM, which were used in \*systemic\* \*administration\* and intra-arterial infusion, was demonstrated. 1) In experimental study, radiation and IL-2 indicated the synergic effects on the tumor growth inhibition. 2) Radiotherapy and \*IFN\*-\*beta\* for advanced head and neck and pelvic \*tumor\* were successful in \*tumor\* effects and tolerable in side effects. 3) The clinical trial showed that pathological effects and clinical \*tumor\* response (CR rate) of radiation and LC9018 for cervical \*cancer\* stage Iib, III were significantly better than those of radiotherapy alone. These data suggested that the \*treatment\* of radiation and BRM was useful and should be considered in multimodal \*therapy\* for \*cancer\*.

**7/3,K/5 (Item 1 from file: 159)**

DIALOG(R) File 159:Cancerlit

(c) format only 2002 Dialog Corporation. All rts. reserv.

01657261 PMID: 89650513

**INTERFERON USE DURING OTHER VIRUS INFECTIONS.**

Cesario; Yousefi; Carandang; Tilles

Dept. of Medicine, Univ. of California Irvine Medical Center, 101 City Drive South, Orange, CA 92668

Non-serial 1987, The Interferon System. A Current Review to 1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 447-52, 1987.

Document Type: MONOGRAPH; REVIEW; REVIEW, TUTORIAL

Languages: ENGLISH

Main Citation Owner: NOTNLM

Record type: Completed

As clinical applications of human interferon (HuIFN) in \*treatment\* of respiratory viruses, herpesviruses, and hepatitis viruses are reviewed in other sections of the book, the present chapter covers therapeutic trials in which the HuIFN...

... survived their disease; and the virus was detected at death in all pts, indicating no beneficial effect. In none of three reports on intrathecal and \*systemic\* \*administration\* of IFN to subacute sclerosing panencephalitis pts could significant benefits be observed. Apparent success in treating juvenile laryngeal papillomatosis using 3 million units of IFN...

... in several studies in which condylomata acuminata was treated with IFN, using im injections or direct injection of the lesions. Use of human fibroblast-derived \*IFN\*-\*beta\* administered in droplet form 6-8 times a day to pts with adenovirus epidemic keratoconjunctivitis appeared to shorten the length of the disease, provide relief...

... Kaposi's sarcoma. These studies are described, and it is concluded from the results that a limited number of such pts will respond to IFN \*therapy\*. However, complete responses (disappearance of the \*tumor\*) could be expected in less than a quarter of the pts, even in the most optimistic of the studies. (25 Refs)

?ds



Set	Items	Description
S1	0	(SYSTEMIC (W) INTERFERON (W) BETA (W) ADMINISTRATION)
S2	0	(SYSTEMIC (W) BETA (W) INTERFERON (W) ADMINISTRATION)
S3	11055	(BETA (W) INTERFERON) OR (IFN (W) BETA) OR (INTERFERON (W) BETA)
S4	4014	S3 (S) (TREATMENT OR THERAPY)
S5	942	S4 (S) (CANCER OR TUMOR)
S6	8	S5 AND (SYSTEMIC (W) ADMINISTRATION)
S7	5	RD (unique items)
?s s4 and (cancer or tumor)		
	4014	S4
	826371	CANCER
	1064068	TUMOR
S8	1283	S4 AND (CANCER OR TUMOR)
?s s8 and review		
	1283	S8
	411687	REVIEW
S9	26	S8 AND REVIEW
?rd		
...completed examining records		
S10	17	RD (unique items)
?t s10/3,k/all		

**10/3,K/1 (Item 1 from file: 155)**  
 DIALOG(R) File 155:MEDLINE(R)  
 (c) format only 2004 The Dialog Corp. All rts. reserv.

15987443 PMID: 12766484

**Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis.**

Chawla-Sarkar M; Lindner D J; Liu Y-F; Williams B R; Sen G C; Silverman R H; Borden E C

Center for Drug Discovery and Development, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

Apoptosis - an international journal on programmed cell death (United States) Jun 2003, 8 (3) p237-49, ISSN 1360-8185 Journal Code: 9712129

Contract/Grant No.: AI 34039; AI; NIAID; CA 44059; CA; NCI; R01 CA 90914; CA; NCI

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

...are a family of cytokines with pleiotropic biological effects mediated by scores of responsive genes. IFNs were the first human proteins to be effective in \*cancer\* therapy and were among the first recombinant DNA products to be used clinically. Both quality and quantity of life has been improved in response to IFNs in various malignancies. Despite its beneficial effects, unraveling the mechanisms of the anti-\*tumor\* effects of IFN has proven to be a complex task. IFNs may mediate anti-\*tumor\* effects either indirectly by modulating immunomodulatory and anti-angiogenic responses or by directly affecting proliferation or cellular differentiation of \*tumor\* cells. Both direct or indirect effects of IFNs result from induction of a subset of genes, called IFN stimulated genes (ISGs). In addition to the...

...DAP kinase), phospholipid scramblase, galectin 9, IFN regulatory factors (IRFs), promyelocytic leukemia gene (PML) and regulators of IFN induced death (RIDs). In vitro IFN-alpha, \*IFN\*-\*beta\* and IFN-gamma induced apoptosis in multiple cell lines of varied histologies. This \*review\* will emphasize possible mechanisms and the role of ISGs involved in mediating apoptotic function of IFNs.

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

13652085 PMID: 9345398

**Human interferon omega--a \*review\*.**

Adolf G R

Department of Cell Biology, Boehringer Ingelheim Research and Development, Vienna, Austria.

Multiple sclerosis (Houndmills, Basingstoke, England) (ENGLAND) 1995,

1 Suppl 1 pS44-7, ISSN 1352-4585 Journal Code: 9509185

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**Human interferon omega--a \*review\*.**

... 10(8) U mg-1; potent antiviral activity against several DNA and RNA viruses has been demonstrated. IFN-omega inhibits proliferation of a variety of \*tumor\* cell lines in vitro. The protein stimulates natural killer cell activity, enhances expression of major histocompatibility complex class I (but not class II) antigens and...

... does not cross-react with antisera or monoclonal antibodies in immunoassays or antiviral neutralization bioassays. Antibodies induced in patients by long-term IFN-alpha 2 \*therapy\* that block IFN-alpha 2 activity do not inactivate IFN-omega. As IFN-omega, like other human IFNs, has a species-restricted biological activity, evaluation...

**10/3,K/3 (Item 3 from file: 155)**

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

13280557 PMID: 8984675

**Experimental immunotherapies for multiple sclerosis.**

Martin R; McFarland H

Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.

Springer seminars in immunopathology (GERMANY) 1996, 18 (1) p1-24,

ISSN 0344-4325 Journal Code: 7910384

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

...PLP in the context of MHC/HLA-class II molecules, express a restricted number of T cell receptor (TCR) molecules and secrete interferon-gamma and \*tumor\* necrosis factor-alpha/beta. Understanding the pathogenetic steps in lesion development at the molecular level led to highly specific immunotherapies for EAE targeting each individual...

... approach is reflected by the effect of interferon-beta on lesion development in MS. The recent approval for the use of interferon-beta for the \*treatment\* of relapsing-remitting MS has raised great interest in examining novel strategies for immunotherapies in MS. The basic concepts as well as the current candidates for such new immunotherapies will be outlined in this short \*review\*.

**10/3,K/4 (Item 4 from file: 155)**

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

12758440 PMID: 7571029

**Long-lasting complete remission of pulmonary metastases consequent to renal cell carcinoma obtained with interferon-beta \*therapy\*: \*review\* of the literature and a case report.**

Scoconi C; Torresi U; Di Giuseppe M  
Department of Oncology, Hospital of Macerata, Italy.  
Tumori (ITALY) May-Jun 1995, 81 (3) p201-3, ISSN 0300-8916  
Journal Code: 0111356  
Document type: Case Reports; Journal Article; Review; Review of Reported Cases  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: Completed

**Long-lasting complete remission of pulmonary metastases consequent to renal cell carcinoma obtained with interferon-beta \*therapy\*: \*review\* of the literature and a case report.**

This case report describes a complete remission of pulmonary metastases, consequent to renal \*cancer\*, achieved with interferon-beta \*therapy\*. After nephrectomy (July 1990), this female patient was proposed for therapeutic assessment: vinblastine chemotherapy was carried out for 10 cycles, whereas concomitant immunotherapy of interferon-alpha was discontinued after 30 days owing to lack of tolerability. In replacement, \*interferon\*-beta administration from the 5th cycle of chemotherapy at the dose of 3 MIU 3 times a week was well tolerated. \*Interferon\*-beta was interrupted 27 months later, due to an increase in transaminase levels. Partial remission of pulmonary metastases was assessed after 9 months of \*interferon\*-beta \*therapy\*, and a complete remission was assessed after 1 and 2 years of \*therapy\*. In November 1994, the patient was still in good clinical conditions and disease-free after 37 months from the achievement of complete remission.

10/3,K/5 (Item 5 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2004 The Dialog Corp. All rts. reserv.

12514798 PMID: 14553875

**Autoimmune aspects of cytokine and anticytokine therapies.**

Krause Irit; Valesini Guido; Scrivo Rossana; Shoenfeld Yehuda  
Nephrology and Dialysis Unit, Schneider's Children Medical Center of Israel, Petah-Tiqva, Israel.

American journal of medicine (United States) Oct 1 2003, 115 (5)  
p390-7, ISSN 0002-9343 Journal Code: 0267200

Document type: Journal Article; Review; Review, Tutorial  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: Completed

Cytokines and anticytokines are used increasingly in the treatment of immune, autoimmune, inflammatory, infectious, and malignant disorders. Commonly used treatments include the anti-\*tumor\* necrosis factor agents interferon alpha, \*interferon\* beta, \*interferon\* gamma, and interleukin 2. Several autoimmune phenomena have been reported in patients treated with these substances. This \*review\* summarizes the published data on the autoimmune manifestations associated with cytokine and anticytokine therapies, as well as describes possible mechanisms of these phenomena.

...; Type II--therapeutic use--TU; Interferon-alpha--adverse effects--AE; Interferon-alpha--therapeutic use--TU; Interferon-beta--adverse effects--AE; Interferon-beta--therapeutic use--TU; \*Tumor\* Necrosis Factor--antagonists and inhibitors--AI

Chemical Name: Cytokines; Interferon-alpha; \*Tumor\* Necrosis Factor; Interferon-beta; Interferon Type II

10/3,K/6 (Item 6 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2004 The Dialog Corp. All rts. reserv.

12385886 PMID: 12769749

**Anti-cytokines and cytokines in the treatment of rheumatoid arthritis.**

Taylor Peter C

The Kennedy Institute of Rheumatology Division, Faculty of Medicine,  
Imperial College London, 1 Aspenlea Road, London, W6 8LH.  
peter.c.taylor@ic.ac.uk

Current pharmaceutical design (Netherlands) 2003, 9 (14) p1095-106,  
ISSN 1381-6128 Journal Code: 9602487

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... in part due to very considerable progress in understanding the important role of cytokines in the immunopathogenesis of this disease. The major focus of this \*review\* is on the rationale for targeting TNFalpha and IL-1 in rheumatoid arthritis and the results of clinical studies designed to assess the validity of...

... modest anti-inflammatory efficacy and an effect on X-ray indicative of retardation of joint damage. Other pro-inflammatory cytokines representing potential therapeutic targets include \*interferon\*--\*beta\*, \*interferon\*--alpha, IL-6, IL-15, IL-17 and IL-18. I will consider preliminary data, where available, arising from clinical trials designed to inhibit the activity of such molecules. In this \*review\* I will also discuss the rationale and preliminary data for other potential therapeutic strategies designed to augment the activity of anti-inflammatory cytokines such as...

...; Antirheumatic Agents--pharmacokinetics--PK; Arthritis, Rheumatoid--metabolism--ME; Clinical Trials; Cytokines--biosynthesis--BI; Interleukin-1--antagonists and inhibitors--AI; Interleukin-1--biosynthesis--BI; Treatment Outcome; \*Tumor\* Necrosis Factor--antagonists and inhibitors--AI; \*Tumor\* Necrosis Factor--biosynthesis--BI

Chemical Name: Antirheumatic Agents; Cytokines; Interleukin-1; \*Tumor\* Necrosis Factor

10/3,K/7 (Item 7 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

12190645 PMID: 12527624

**Interferons and their application in the diseases of the lung.**

Antoniou Katerina M; Ferdoutsis Emmanouil; Bouros Demosthenes

Interstitial Lung Disease Unit, Department of Pneumology, Medical School University of Crete, Crete, Greece.

Chest (United States) Jan 2003, 123 (1) p209-16, ISSN 0012-3692  
Journal Code: 0231335

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... IFNs, as follows: IFN-alpha; IFN-beta; and IFN-gamma. IFNs are being investigated and applied in various respiratory disorders, including interstitial lung diseases, lung \*cancer\*, malignant mesothelioma, malignant pleural effusions, and respiratory infections. Recent promising preliminary results concerning patients with idiopathic pulmonary fibrosis who have been treated with IFN-gamma should prompt the performance of further confirmatory well-designed multicenter trials. IFN-gamma is emerging as an important cytokine for use in the \*treatment\* of patients with infectious diseases, including multidrug-resistant pulmonary TB. A better understanding of IFN biology, indications, side effect profiles, and toxicity management will aid in optimizing its use in the \*treatment\* of patients. The purpose of this article is, therefore, to \*review\* the current clinical use of IFNs in the \*treatment\* of patients with respiratory diseases.

10/3,K/8 (Item 8 from file: 155)

DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2004 The Dialog Corp. All rts. reserv.

12069722 PMID: 12395925

**mda-7 (IL-24): signaling and functional roles.**

Sarkar Devanand; Su Zao-zhong; Lebedeva Irina V; Sauane Moira;  
Gopalkrishnan Rahul V; Dent Paul; Fisher Paul B

Department of Pathology, Herbert Irving Comprehensive Cancer Center,  
Columbia University, College of Physicians and Surgeons, New York, NY  
10032, USA.

BioTechniques (United States) Oct 2002, Suppl p30-9, ISSN 0736-6205  
Journal Code: 8306785

Contract/Grant No.: CA35675; CA; NCI; CA87170; CA; NCI; CA88906; CA; NCI;  
DK52825; DK; NIDDK; P30-AR44535; AR; NIAMS

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... chemical or biological methods, provides a possible therapeutic intervention. "Differentiation therapy" is well documented in several model systems. These include melanoma, in which treatment with \*interferon\*-  
\*beta\* and the protein kinase C activator mezerein induces irreversible growth arrest and terminal differentiation culminating in programmed cell death. Subtraction hybridization between terminally differentiated and...

... Based on this consideration, mda-7 was renamed IL-24. Secondly if delivered by means of an adenoviral vector, mda-7 induces selective apoptosis in \*cancer\* cells of diverse origin, while sparing their normal cellular counterparts. As such, mda-7 has become a novel tool for \*cancer\* gene \*therapy\* and is currently undergoing phase II clinical trials to determine its clinical efficacy in patients. The present \*review\* examines the biological properties of mda-7 and the signaling pathways that contribute to its unique \*cancer\*-specific apoptosis-inducing properties.

...; PH; Neoplasms--drug therapy--DT; Neoplasms--therapy--TH; Pancreatic Neoplasms--genetics--GE; Pancreatic Neoplasms--pathology--PA; Rats; Recombinant Fusion Proteins--physiology--PH; Safety; Signal Transduction; \*Tumor\* Cells, Cultured--pathology--PA

10/3,K/9 (Item 9 from file: 155)

DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2004 The Dialog Corp. All rts. reserv.

11527502 PMID: 11696695

**Cytokines and immune response in the \*tumor\* microenvironment.**

Mocellin S; Wang E; Marincola F M

Department of Transfusion Medicine, Clinical Center, National Cancer  
Institute, National Institutes of Health, Bethesda, Maryland 20814, USA.

Journal of immunotherapy (Hagerstown, Md. - 1997) (United States)  
Sep-Oct 2001, 24 (5) p392-407, ISSN 1524-9557 Journal Code: 9706083

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**Cytokines and immune response in the \*tumor\* microenvironment.**

... last few decades a wealth of evidence has been gathered on the potential role that the immune system (IS) can play in the fight against \*cancer\* . Together with cell surface adhesion molecules, cytokines (CKs) mediate the activities of IS cells. Therefore, CK kinetics may represent a mirror of the immunologic phenomena occurring in the \*tumor\* microenvironment, where immune and malignant cells interact. Yet, CKs are currently used in a clinical setting to polarize the immune response against \*cancer\* . Despite the large amount of information available on IS physiology, little is known about the role of CKs in modulating the effectiveness of immunotherapy clinical trials aimed at the treatment of

patients with \*cancer\*. This underscores our relative ignorance about the complex cascade of events that lead to \*tumor\* rejection. Here, we \*review\* the properties of some CKs believed to be particularly relevant to \*tumor\* immunology (i.e., interleukin [IL]-10, transforming growth factor-\*beta\*, \*interferon\* -gamma, IL-2, IL-4, and IL-12). We summarized the experience gained with these CKs in vitro, in animal models, and in human beings...

... challenges that characterize this fascinating field of oncology. In addition, we added a short section in which a broad view of CKs released in the \*tumor\* microenvironment is proposed to underline the variety of factors that contribute to the complexity of \*tumor\*-IS interactions.

10/3,K/10 (Item 10 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2004 The Dialog Corp. All rts. reserv.

10853464 PMID: 10983302

**[Interferon beta and copolymer-1: mechanism of action and clinical effects in multiple sclerosis]**

Interferon beta oraz copolimer-1: mechanizm dzialania oraz efekty kliniczne w stwardnieniu rozsianym.

Losy J

Zaklad Neuroimmunologii Klinicznej Katedry Neurologii AM w Poznaniu.

Neurologia i neurochirurgia polska (POLAND) 2000, 34 (3 Suppl) p63-9

, ISSN 0028-3843 Journal Code: 0101265

Document type: Journal Article; Review; Review, Tutorial ; English  
Abstract

Languages: POLISH

Main Citation Owner: NLM

Record type: Completed

In the paper the \*review\* of clinical trials with interferon beta and copolimer-1 in the \*treatment\* of multiple sclerosis was presented. The effect of \*interferon\* \*beta\* and copolimer-1 on relapse frequency, disability and MRI activity has been described. The mechanism of action of \*interferon\* \*beta\* and copolimer-1 in MS was discussed.

...; pharmacology--PD; Clinical Trials; Interferon Type II--metabolism--ME; Interferon-beta--pharmacology--PD; Multiple Sclerosis--immunology--IM; Peptides--pharmacology--PD; Recurrence; T-Lymphocytes--metabolism--ME; \*Tumor\* Necrosis Factor--metabolism--ME; Vascular Cell Adhesion Molecule-1--metabolism--ME

Chemical Name: Adjuvants, Immunologic; Peptides; \*Tumor\* Necrosis Factor; Vascular Cell Adhesion Molecule-1; copolymer 1; Interferon-beta; Interferon Type II

10/3,K/11 (Item 11 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2004 The Dialog Corp. All rts. reserv.

10690079 PMID: 10807049

**The genes of interferons and interferon-related factors: localization and relationships with chromosome aberrations in \*cancer\*.**

Haus O

Department of Clinical Genetics, University Medical School, Bydgoszcz, Poland. haus@aci.amb.bydgoszcz.pl

Archivum immunologiae et therapiae experimentalis (POLAND) 2000, 48

(2) p95-100, ISSN 0004-069X Journal Code: 0114365

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**The genes of interferons and interferon-related factors: localization and relationships with chromosome aberrations in \*cancer\*.**

The paper presents a \*review\* of data on the localization of interferons

(IFNs) and IFN system genes and their relationship with human diseases, mainly \*cancer\*. Genes of interferon system proteins are located at the sites of breakpoints of the structural chromosome aberrations in \*cancer\*. Thus, any of them are rearranged or translocated in various \*tumor\* types. As the activity of these genes plays a role in \*cancer\* development, their rearrangements may be one of the crucial points in the pathogenesis of some \*cancer\* types. Besides, they also take part in organism immunity against viral infections. Transfection experiments with IFN system genes have proved the influence of these genes on \*cancer\* behavior and may serve as a basis for clinical gene therapy. IFN-alpha and \*IFN\*-beta\* genes are located at 9p21-22, the site of frequent homozygotic deletions in \*cancer\*. Their loss sensitizes cells to the growth inhibitory actions of exogenous IFNs. The IFN-gamma gene, a representative of class II genes, is located at 12q24.1. Transfection of class II IFNs genes to \*cancer\* cell lines causes cell proliferation arrest and augments the expression of HLA antigens, which may be clinically useful in stimulating the immune destruction of \*tumor\* cells. The interferon regulatory factor 1 (IRF-1) gene is located at 5q31, the site of common deletions in myelodysplastic syndromes (MDS) and secondary leukemias. The loss of heterozygosity of this gene was found in MDS, which proves that IRF-1 may be a \*tumor\* suppressor. A transfection of its gene causes neoplastic transformation arrest. The double-stranded RNA-activated protein kinase (PKR) gene is located at 2p21-22, a...

... of a wild type PKR gene reverses neoplastic transformation caused by transfection of a mutated PKR gene, proving that PKR acts as a dominant negative \*cancer\* suppressor.

10/3,K/12 (Item 12 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2004 The Dialog Corp. All rts. reserv.

10113633 PMID: 7516642

**Intracavitary treatment of malignant pleural and peritoneal effusions in \*cancer\* patients.**

Gebbia N; Mannino R; Di Dino A; Maxhouni L; Bellone N; Cinque L; Liuzza A ; La Motta P; Cannata G; Gulotta G; et al  
Chair of Chemotherapy, University of Palermo, Italy.  
Anticancer research (GREECE) Mar-Apr 1994, 14 (2B) p739-45, ISSN 0250-7005 Journal Code: 8102988  
Document type: Journal Article; Review; Review, Tutorial  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: Completed

**Intracavitary treatment of malignant pleural and peritoneal effusions in \*cancer\* patients.**

Authors present a \*review\* of the intracavitary treatment of malignant effusions in \*cancer\* patients, experience with tetracycline, mechlorethamine, quinacrine, radio-isotopes, \*interferon\* \*beta\* and interferon alpha are reviewed. Personal experience with interferon alpha is reported.

10/3,K/13 (Item 13 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)  
(c) format only 2004 The Dialog Corp. All rts. reserv.

09608428 PMID: 7679433

**Effects of interferons and cytokines on melanoma cells.**

Garbe C; Krasagakis K  
Department of Dermatology, University Medical Center Steglitz, Free University of Berlin, Germany.

Journal of investigative dermatology (UNITED STATES) Feb 1993, 100 (2 Suppl) p239S-244S, ISSN 0022-202X Journal Code: 0426720

Document type: Journal Article; Review; Review, Tutorial  
Languages: ENGLISH

Main Citation Owner: NLM  
Record type: Completed

This **\*review\*** summarizes recent information on the effects of immunomodulatory cytokines on human melanoma cells. The action of interferon (IFN)-alpha, -beta, and -gamma has been extensively...

... effect on melanoma cells with the highest growth inhibition caused by IFN-beta. Proliferation was also inhibited by interleukin (IL) 1-alpha and -beta, and **\*tumor\*** necrosis factor (TNF)-alpha. For IL-4, both growth-stimulatory and -inhibitory properties have been reported. Cellular differentiation in terms of melanin synthesis, formation of...

... antigen (HLA) class I molecules were found upregulated by all IFNs and by TNF-alpha, associated with a marked increase of melanoma cell lysis by **\*tumor\*** infiltrating lymphocytes in vitro. HLA class II molecules were de novo expressed or enhanced by IFN-gamma and TNF-alpha. The adhesion molecules ICAM-1...

... the antitumoral activity of cytokines in vivo. In vivo application of cytokines as well as combinations with cytotoxic drugs, therefore, may be promising for future **\*treatment\*** strategies.

10/3,K/14 (Item 14 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2004 The Dialog Corp. All rts. reserv.

07535967 PMID: 2442112

**Interferons in the treatment of multiple myeloma.**

Ohno R

International journal of cancer. Supplement = Journal international du cancer. Supplement (UNITED STATES) 1987, 1 p14-20, ISSN 0898-6924  
Journal Code: 8710267

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

A **\*review\*** of the clinical studies in which interferons have been involved has shown that they may have a role in the treatment of multiple myeloma. Twelve...

... previously treated and that which was not treated. At least clinically, therefore, there seems to be no cross-resistance between alpha-interferons and conventional anti-**\*tumor\*** drugs. A randomized study comparing low-dose leukocyte interferon with intermittent high-dose melphalan-prednisone has given a lower response rate for **\*interferon\***. **\*Beta\***- and gamma-interferons have not yet been extensively studied. They have been used at low doses producing an objective response in 7% of 68 and 2% of 45 evaluable cases, respectively. Since the myelosuppression of interferons is transient and, after discontinuation of interferon **\*therapy\***, peripheral blood cells usually recover within a week, it may be possible to use interferon in combination with agents that have strong myelosuppressive effects provided ...

10/3,K/15 (Item 15 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2004 The Dialog Corp. All rts. reserv.

07410036 PMID: 2436387

**The interferon system. A **\*review\*** of biological principles and clinical uses]**

Das Interferon-System. Eine Übersicht über biologische Grundlagen und klinische Anwendungen.

Schneider F J

Zeitschrift für die gesamte innere Medizin und ihre Grenzgebiete (



GERMANY, EAST) Nov 15 1986, 41 (22) p613-8, ISSN 0044-2542  
Journal Code: 21730470R  
Document type: Journal Article ; English Abstract  
Languages: GERMAN  
Main Citation Owner: NLM  
Record type: Completed

**The interferon system. A \*review\* of biological principles and clinical uses]**

... activity, their antiproliferative and immunoregulatory activities. Clinical trials showed that interferons can be used as therapeutic agents in viral infections and malignant diseases. Results of \*treatment\* in certain viral infections or virally induced tumors and some particular haematologic malignancies are very good. Many frequent forms of tumors still respond less or not at all to interferon \*treatment\*. Interferons have many different effects in vivo and can act synergistically with other agents. Further success in \*cancer\* \*therapy\* can therefore be expected from investigations on optimum dose schedule and effective combination regimes.

10/3,K/16 (Item 1 from file: 159)  
DIALOG(R)File 159:Cancerlit  
(c) format only 2002 Dialog Corporation. All rts. reserv.

02061949 PMID: 94698817

**Prognostic meaning of peritoneal cytology in Stage I of endometrial \*cancer\* and new adjuvant therapy (Meeting abstract).**

Gallo; Graziano; De Santis V; Di Meglio G; Sarto; Maffeo  
Dept. of Gynaecological Oncology, Natl. Cancer Inst., Naples, Italy  
Non-serial 1993, Gynaecological Oncology, 8th International Meeting of the European Society of Gynaecological Oncology. June 9-12, 1993, Barcelona, Spain, 1993.,  
Document Type: JOURNAL ARTICLE  
Languages: ENGLISH  
Main Citation Owner: NOTNLM  
Record type: Completed

**Prognostic meaning of peritoneal cytology in Stage I of endometrial \*cancer\* and new adjuvant therapy (Meeting abstract).**

Authors conducted a retrospective \*review\* of clinical evolution of I FIGO stage endometrial adenocarcinoma with peritoneal cytology positive (ppc). The course of disease was studied in a group of 20...

... cytology as prognostic factor, they thought that ppc can identify a group in need of adjuvant therapy in pts affected by I FIGO stage endometrial \*cancer\*. An adjuvant therapy was introduced, 2 years ago, for these pts: ip infusion of carboplatin and \*IFN\*-*\*beta\**. This study is in progress.

10/3,K/17 (Item 2 from file: 159)  
DIALOG(R)File 159:Cancerlit  
(c) format only 2002 Dialog Corporation. All rts. reserv.

01657267 PMID: 89650519

**INTERFERON: POTENTIAL USE IN SOLID TUMORS.**

Bonnem  
Clinical Res. Div., Schering Corp., Kenilworth, NJ 07033  
Non-serial 1987, The Interferon System. A Current Review to 1987. Baron S et al, eds. The University of Texas Medical Branch Series in Biomedical Science, Austin, TX, University of Texas Press, p. 507-16, 1987.

Document Type: MONOGRAPH; REVIEW; REVIEW, TUTORIAL  
Languages: ENGLISH  
Main Citation Owner: NOTNLM  
Record type: Completed

In this \*review\* of the potential use of interferon (IFN) in the \*treatment\* of solid tumors, patients (pts) with advanced melanoma are reported to have shown little response when treated with leukocyte-derived IFN-alpha. When this IFN was combined with cimetidine, \*tumor\* regression was observed in 4/15 pts in one study and in 6/16 in another; however, in a third study, in which recombinant IFN...

... could not be confirmed. Like the malignant melanoma, renal cell carcinoma (RCC) has a low, yet definite response rate (10-30%). No published data for \*treatment\* of RCC with recombinant \*IFN\*-\*beta\* are available, but 6/35 RCC pts administered IFN-gamma showed responses. For ovarian \*cancer\*, 2/15 previously treated pts responded to leukocyte-derived IFN-alpha in one study, 1/15 pts in another. Activity was also demonstrable for recombinant IFN-gamma; and the most promising results were obtained when 14 previously treated ovarian \*cancer\* pts were administered recombinant IFN-alpha 2b (four surgically documented complete responses, one partial response, and one clinical complete response, with duration of response of 5-14+ mo). For bladder carcinoma, there have been few well-designed trials involving \*treatment\* with IFNs. Among the trials mentioned was a Phase I-II trial of rIFN-alpha 2b administered intravesically to 17 bladder \*cancer\* pts; complete response occurred in 6/8 with carcinoma in situ, 0/8 with papillary carcinoma, and 1/1 with both histologies. For breast carcinoma...

...of B symptoms, a less altered immune defect (higher T4/T8 ratio), and no prior opportunistic infection. For malignant glioma, initial trials indicated responses to \*treatment\* with \*IFN\*-\*beta\* and with nonrecombinant IFN-alpha; to determine the impact on survival, however, larger numbers of pts, longer follow-ups, and comparisons with results of standard \*therapy\* are required. For lung carcinoma or gastrointestinal malignancies, none of the IFNs have demonstrated any antitumor activity. Future directions in the IFN \*treatment\* of solid tumors are discussed. (45 Refs)

?ds

Set	Items	Description
S1	0	(SYSTEMIC (W) INTERFERON (W) BETA (W) ADMINISTRATION)
S2	0	(SYSTEMIC (W) BETA (W) INTERFERON (W) ADMINISTRATION)
S3	11055	(BETA (W) INTERFERON) OR (IFN (W) BETA) OR (INTERFERON (W) BETA)
S4	4014	S3 (S) (TREATMENT OR THERAPY)
S5	942	S4 (S) (CANCER OR TUMOR)
S6	8	S5 AND (SYSTEMIC (W) ADMINISTRATION)
S7	5	RD (unique items)
S8	1283	S4 AND (CANCER OR TUMOR)
S9	26	S8 AND REVIEW
S10	17	RD (unique items)

?logoff

```

14may04 16:05:14 User259876 Session D621.2
$5.40      1.688 DialUnits File155
$3.99  19 Type(s) in Format  3
$3.99  19 Types
$9.39 Estimated cost File155
$2.12      0.717 DialUnits File159
$0.78   3 Type(s) in Format  3
$0.78   3 Types
$2.90 Estimated cost File159
OneSearch, 2 files,  2.405 DialUnits FileOS
$1.50 TELNET
$13.79 Estimated cost this search
$14.18 Estimated total session cost   2.501 DialUnits

```

### Status: Signed Off. (7 minutes)